oncolog-hematolog
ro
oncologie
pot deveni markeri în diagnostic şi vincristin, bleomicin). Deşi bleomicinul Cancerul tubar (Fallopian)
urmărire post-terapeutică datorită fe- produce fibroză pulmonară şi are doză Reprezintă o formă rară de cancer
nomenelor de pubertate precoce sau cumulativă cu contraindicaţii la vârstnici ovarian, în majoritatea cazurilor inva-
sarcinii ex­trauterine la femeia adultă. sau etoposidul poate produce leucemii, zia trompei fiind cauzată de evoluţia
Tratamentul este chirurgical, dar, în disfuncţii renale, hipertensiune sau locală a bolii. Tipul histologic cel mai
stadiile II-IV se poate recomanda şi sindrom Raynaud, beneficiul terapeutic comun este adenocarcinomul seros
tratament adjuvant, deşi avantajul trebuie evidenţiat. În cazul pacienţilor papilar, iar în forma pură este însoţit de
acestui tratament nu a fost dovedit în cu contraindicaţii la bleomicină şi/sau mutaţii BRCA1 şi BRCA2, cu o bogată
trialuri clinice randomizate. Răspunsul etoposid, tratamentul trebuie să cu- istorie familială. Evoluţia bolii este mai
terapeutic este obţinut în proporţie de prindă o sare de platină şi paclitax­el, ales retroperitoneală şi ganglionară.
30-50%, atunci când regimul de chimio- deşi nu ex­istă studii randomizate în Tratamentul este chirurgical, iar trata-
terapie are la bază o sare de platină. acest sens. mentul adjuvant citostatic asociază de
Regimurile de chimioterapie cele mai Recidiva se tratează chirurgical, ur- elecţie paclitax­el şi carboplatin. Dato-
cunoscute sunt CAP (ciclofosfamidă, mată de tratament fie chimioterapic sau rită rarităţii bolii, nu ex­istă studii de su-
dox­orubicin, cisplatin), BEP (bleomicin, radioterapie, fie tratament hormonal pravieţuire la pacienţii care efectuează
etoposid, cisplatin) şi PVB (cisplatin, (agenţi progestativi sau analogi LH-RH). tratament adjuvant chimioterapic. n
Bibliografie
1. David M. O’Malley*, Masoud Azodi, Anita Makkenchery, Ja- 199349;30.
cob Tangir, Jessica McAlpine Weekly topotecan in heavily pre- 13. Bookman M.A. GOG 182-ICON5:5 arm phase III randomized
treated patients with recurrent epithelial ovarian carcinoma trial of paclitaxel (P) and carboplatin(C) vs combination with
Gynecologic Oncology 98 (2005) 242-248. gemcitabine (G), PEG liposomal doxorubicin (D) or topotecan
2. Cohn D.E. et al. Gynecol Oncol. 2006; 102:134-139. (T) in patients with advanced stage epithelial ovarian (EOC)
3. Friberg G. et al. J Clin Oncol. 2006; 24:260s (Abstract 5018). or primary peritoneal (PPC) carcinoma. Proc Am Soc Clin On-
4. Bookman M.A., Darcy K.M. et al. Evaluation of monoclonal col 2006;24 (abstr.5002).
humanized anti-HER2 antibody, trastuzumab, in patents with 14. Rothenberg M.I., Liu P.Y. et al. Combined intraperitoneal
recurrent or refractory ovarian or primary peritoneal carci- and intravenous chemotherapy for women with optimally de-
noma with overexpression of HER2: a phase II trial of the Gy- bulked ovarian cancer: results from an inter group phase II
necologic Oncology Group. J. Clin Oncol 2003:21:283, trial. J Clin Oncol 2003;21; 1313
5. Ozols R.F., Bundy B.N. et al. Phase III trial of carboplatin and 15. Walker JL, Armstrong DK, et al. Intraperitoneal catheter out-
paclitaxel compared with cisplatin and paclitaxel in patients comes in a phase III trial of intravenous versus intraperitoneal
with optimally resected stage III ovarian cancer: a Gyneco- chemotherapy in optimal stage III ovarianand primary perito-
logic Oncology Group study. J. Clin Oncol 2003:21:3194. neal cancer: a GOG Study. Gynecol Oncol 2006;100; 27
6. Trimbos J.B., Parmar M. et al. International Collaborative 15. Fujiwara K., Sakuragy N., et al. First-line intraperitoneal car-
Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in boplatin-based chemotherapy for 165 patients with epithelial
Ovarian Neoplasm trial: two parallel randomized phase III ovarian carcinoma: results of long term follow-up. Gynecol
trials of adjuvant chemotherapy in patients with early stage Oncol 2003;90; 637.
ovarian carcinoma (comment). J Natl Cancer Inst 2003:95:105. 16. Markman M., Liu P.Y. et al. Phase III randomized trial of 12 vs
7. Alberts D.S., Green S. et al. Improved therapeutic index of car- 3 months of maintenance paclitaxel in patients with advanced
boplatin plus cyclophosphamide versus cisplatin plus cyclo- ovarian cancer after complete response to platinum and pacli-
phosphamide: final report by the Southwest Oncology Group taxel based chemotherapy: a Southwest Oncology Group and
of phase III randomized trial in stages III and IV ovarian can- GOG trial. J Clin Oncol 2003; 21;2560.
cer. J Clin Oncol 1992: 10;706. 17. Markman M., Rothman R. et al. Second-line platinum ther-
8. Piccart M.J., Bertelsen K. et al. Randomized intergroup trial apy in patients with ovarian cancer previously treated with
of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in cisplatn. J Clin Oncol 1991; 9;389.
women with advanced epithelial ovarian cancer: three years 18. Pfisterer J., Weber B. et al. Randomized phase III topotecan
results (comment). J Natl Cancer Inst 2000; 92;699. following carboplatin and paclitaxel in first-line treatment
9. Paclitaxel plus carboplatin versus standard chemotherapy of advanced ovarian cancer: a gynecologic cancer intergroup
with either single agent carboplatin or doxorubicin and cis- trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;
platin in women with ovarian cancer: the ICON3 randomized 98; 1036.
trial. Lancet 2002; 360-505. 19. Silva E.G., Gershenson D.M. et al. The recurrence and the
10. du Bois A., Luck H.J. et al. A randomized clinical trial of cis- overall survivalrates of ovarian serous borderline neoplasms
platin /paclitaxel versus carboplatin/paclitaxel as first line with noninvasive implants in time dependent. Am. J Surg
treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320. Pathol 2006;30;1367.
11. Vascy P.A., Jayson G.C. et al. Phase III randomized trial of 20. Williams S., Blessing J.A. et al. Adjuvant therapy of ovarian
docetaxel carboplatin versus paclitaxel carboplatin as a first germ germ cell tumors with cisplatin, etoposide, and bleomy-
line chemotherapy for ovarian cancer. J Natl Cancer Inst cin: a trial of Gynecologic Oncology Group. J Clin Oncol1994;
2004;96;1682. 12;701.
12. Bertelsen K., Jakobsen A. et al. A prospective randomized 21. Homesley H.D., Bundy B.N. et al. Bleomycin, etoposide and
comparison of 6 and 12 cycles cyclophosphamide, adriamy- cisplatin combination therapy of ovarian granulose cell tu-
cin, and cisplatin in advanced epithelial ovarian cancer: a mors and other stromal malignancies: a GOG Study. Gynecol
Danish Ovarian Study Group trial(DACOVA). Gynecol Oncol Oncol 1999; 72;131.
pag. 16
Nr. 6/martie 2009
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68